Recon: Biden administration to order 200M more COVID vaccine doses; AstraZeneca, EU spar over vaccine supplies

• Biden administration to buy 200 million more doses of Covid vaccine (Politico)
• U.S. CDC sees lower rates of allergic reaction after Pfizer vaccine (Reuters)
• Moderna in talks with US to sell 100 million more COVID-19 vaccine doses (Reuters)
• Eli Lilly, Regeneron's COVID-19 treatments may be weaker against South Africa variant (Reuters)
• Remdesivir, Given to Half of Hospitalized Covid Patients in US, Is Big Win for Gilead — Boosted by Taxpayers (KHN)
• Biden Pledges to Speed Flow of Vaccines to the States (NYTimes)
• WATCH: Biden's Coronavirus Team Gives First Briefing (NPR)
• Millions earmarked for public health emergencies were used to pay for unrelated projects, says inspector general (Washington Post) (Letter)
• Johnson & Johnson confident of rebound as vaccines offer boost for healthcare (FT) (MedtechDive)
• Biden Administration Criticized For Delay In Tackling Opioid Crisis (NPR)
• Senate rules could pose hurdles for vaccine funds (STAT)
• Court orders Rochester General to give experimental COVID treatment to patient (Democrat & Chronicle)

• Global COVID-19 cases surpass 100 million as nations tackle vaccine shortages (Reuters)
• EU pushes for access to AstraZeneca COVID vaccines from UK plants (Reuters) (FT) (NYTimes)
• EU asks AstraZeneca to publish vaccine contract after CEO's disclosures (Reuters)
• Sanofi confirms its will supply over 125 million Pfizer-BioNTech doses to the EU (Reuters)
• AstraZeneca UK vaccine partner says suspicious package made safe, production schedule unaffected (Reuters)
• AstraZeneca to ask Japan's JCR Pharmaceutical to produce COVID-19 vaccine (Reuters)
• Vaccines should be able to be adapted fast to address COVID-19 variants - WHO's Ryan (Reuters)
• COVAX to supply 355 million vaccine doses for Eastern Med this year - WHO official (Reuters)
• Lonza sees months before Swiss COVID-19 vaccine plants hit 'cruising speed' (Reuters)
• With Expensive U.S. COVID-19 Vaccines, Many Countries Look Elsewhere (NPR)

• World surpasses 100M coronavirus cases (The Hill)
• US considering mandatory COVID-19 tests for domestic flyers, CDC official says (The Hill)
• China, India's COVID-19 vaccinations to stretch to late 2022: study (Reuters)
• India's COVAXIN likely effective against UK variant – study (Reuters)
• TimesBrazilian companies discuss seeking direct vaccine supplies (Financial Times)
• 3M CEO expects Covid demand for the company’s N95 masks to be strong throughout 2021 (CNBC)
• Abbott's Panbio antigen test obtains new European approvals for mass COVID-19 screening (Fierce)
• BD study suggests its COVID-19 antigen test better than PCR at detecting infectious individuals (MedtechDive)
• France Rejects Advice To Delay Second Dose Of Pfizer Vaccine (Pink Sheet)
• At-home Covid-19 tests offer promises — and questions (NBC)
• Why N95 Masks Are Still In Short Supply In The U.S. (NPR)
• Eli Lilly teams up with pharma rival GSK and partner Vir for COVID-19 antibody cocktail test (Fierce)
• Some European Countries Move To Require Medical-Grade Masks In Public (NPR)
• Chinese cities using anal swabs to screen COVID-19 infections (Reuters)
• India's Dr.Reddy's ends study of COVID-19 drug Avigan in Kuwait (Reuters)
• Mexico may approve Russian COVID-19 vaccine within days, health official says (Reuters)
• South Africa approves AstraZeneca vaccine for emergency use (Reuters)
• Morocco gets half million doses of Sinopharm Covid-19 vaccine (Reuters)
• Spanish regions cap COVID-19 vaccinations due to slowing supply (Reuters)
• UNICEF signs up Dubai's DP World to help distribute COVID-19 vaccines (Reuters)
• Chile health regulator approves AstraZeneca COVID-19 vaccine for emergency use (Reuters)
• Uganda conducting clinical trials of possible drug against COVID-19 infections – statement (Reuters)

• With All Eyes on Covid-19, Drug-Resistant Infections Crept In (NYTimes)
• Novartis hit by ‘COVID-19-related lockdowns’ in Q4 (PMLive)
• For Biosimilars, A Mid-Review Cycle Product Quality Discussion Appears To Be A Bad Omen (Pink Sheet)
• AstraZeneca scores new goal on the pipeline front, adding its first AI-generated target to the portfolio (Endpoints)
• Can Biosimilar Orphans Increase Health System Sustainability In The UK? (Pink Sheet)
• NICE recommends Celgene's REVLIMID for multiple myeloma (Pharmafile)
• EU Crunch Time For Two Drugs That Lost Their Fast-Track Status (Pink Sheet)
• Horizon Therapeutics Sets Sights on Blockbuster Sales, Broader Pipeline (GEN)
• Agios readies FDA filing as anemia drug clears another phase 3 (Fierce)
• Sanofi joins fellow French firms in venture to boost digital health solutions (Fierce)
• CDER Planning Guidances On Single-Trial Approvals, Real-World Evidence (Pink Sheet)
• Safety finding weighs on Pfizer's inflammation drug, and could spell trouble for others (BioPharmaDive) (Endpoints)
• Ex-MD Anderson chief DePinho is helping launch another biotech — and he's sticking with familiar ground (Endpoints)
• As targeted therapies get ever more precise, Deerfield unveils $50M bet on an Harvard professor's chemistry insights (Endpoints)
• Foresite returns to the SPAC well, as investors wonder how long the run can last (Endpoints)
• Leaps by Bayer backs a protein engineering startup taking on Aimmune — and Nestlé — in peanut allergy (Endpoints)
• AstraZeneca CEO Pascal Soriot severs an unusual board connection, steering clear of conflicts while retaining important alliances (Endpoints)
• Vir stock soars on blinded, 8-subject hepatitis B analysis (Fierce)
• GSK transfers malaria vaccine production to India's Bharat Biotech (Economic Times)

• Ventilators, imaging drive GE healthcare profits up 27% as procedures even out (MedtechDive)
• Surmodics drug-coated balloon on par with Medtronic's in study (MedtechDive)
• Delayed NHS MedTech funding mandate policy to launch in April (mobihealthnews)
• Samsung says smartwatch ECG, blood pressure measurement will go live in 31 more countries (mobihealthnews)
• HFE for over-the-counter medical devices and combination products: Nice to have or necessary? (Emergo)

• ‘Use that money wisely’: Coalition urges governments to spend opioid settlement funds on evidence-based efforts (STAT)
• CMS puases three Trump-era proposed rules (Modern Healthcare)
• Judge Doubts Walmart's Preemptive Opioid Suit Can Prevail (Law360)
• Fresenius Asks 3rd Circ. For Partial Redo Of Generics Opinion (Law360)
• Eli Lilly Says HHS Drug Discount Rule Will Cost It Billions (Law360)
• Full Fed. Circ. Won't Take Up Hatch-Waxman Act Venue Limits (Law360)
• Opioid MDL Judge Takes Senior Status, Setting Up Biden Pick (Law360)
• NJ Court Lends Support To FDA Evidence In Mesh Cases (Law360)